F1324

CAS No. ——

F1324( —— )

Catalog No. M30261 CAS No. ——

F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6) with an IC50 of 1 nM. F1324 exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    F1324
  • Note
    Research use only, not for human use.
  • Brief Description
    F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6) with an IC50 of 1 nM. F1324 exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.
  • Description
    F1324 is a potent, high affinity peptidic inhibitor of B cell lymphoma 6 (BCL6) with an IC50 of 1 nM. F1324 exhibits binding t1/2 value of 441 s and has strong inhibition activity against BCL6 PPI.(In Vitro):F1324 binds to BCL6(5-129) with KD and IC50 values of 0.57 nM and 1 nM according to the results of an SPR analysis and cell-free ELISA assay, respectively. F1324 binds BCL6 not only in cell-free but also cellbased conditions.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    IC50: 1 nM (BCL6)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    1765.04
  • Molecular Formula
    C83H121N21O20S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:Ac-{Leu}{Trp}{Tyr}{Thr}{Asp}{Ile}{Arg}{Met}{Ser}{Trp}{Arg}{Val}{Pro}-OH

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Sakamoto K, et al. Discovery of high-affinity BCL6-binding peptide and its structure-activity relationship. Biochem Biophys Res Commun. 2017 Jan 8;482(2):310-316.
molnova catalog
related products
  • PF-03382792

    PF-03382792 (PF-3382792) is a clinical compound under phase 1 investigation for an unknown indication.

  • Methyl syringate

    Methyl syringate has a unique inhibitory activity toward aflatoxin production with a different mode of action from that of gallic acid.

  • Ribostamycin sulfate

    Ribostamycin is a broad-spectrum antimicrobial, inhibits bacterial protein synthesis at the level of 30S and 50S ribosomal subunit binding, also inhibits the chaperone activity of protein disulfide isomerase (PDI), used in pharmacokinetic and nephrotoxicity studies.